Since its introduction in 1995, the chickenpox vaccine has significantly decreased the number of infections, hospitalizations, and deaths associated with the disease. Vaccination is recommended for all children before the age of five years and for nonimmune adults. The vaccine has also contributed to a decline in severe cases and complications, making chickenpox far less of a public health concern.

The chickenpox vaccine contains a weakened form of the varicella-zoster virus, which stimulates the immune system to develop protective antibodies. This means if a vaccinated person is exposed to the virus, their immune system can fight it off more effectively. While the vaccine isn't 100% foolproof, vaccinated individuals who do contract the virus typically experience a much milder form of the disease.

In rare cases, vaccinated individuals can still get chickenpox, known as 'breakthrough' infections. These cases are generally milder and shorter in duration, with fewer blisters and less severe symptoms. Studies indicate that breakthrough rates are low, and complications from these cases are uncommon, highlighting the vaccine's role in controlling the disease's severity.

The chickenpox vaccine is a key tool in reducing the impact of this contagious disease.